Physician profile

Michael David Rosenberg

Diagnostic Radiology · Durham, NC

NPI 1437443892

$195.96

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$33.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $87.32 2021
Encore Medical, LP $50.52 2021
Penumbra, INC. $24.23 2019
Blue Earth Diagnostics $18.13 2024
Siemens Medical Solutions USA, INC. $15.76 2023 Somatom X.Cite, Somatom Force, Somatom Go.Top

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael David Rosenberg

$195.96

in general payments reported 2019-2025

Years
2019-2024
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/5517005/michael-david-rosenberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.